Darlene Posted May 2, 2021 Share Posted May 2, 2021 https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19 PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19 Page 1/2 PREVENTION PROTOCOL lvermectin1 Prevention for high risk individuals 0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours, then one dose weekly* Post COVID-19 exposure prevention2 0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours* Vitamin D3 1,000–3,000 IU/day Vitamin C 500–1,000 mg twice a day Quercetin 250 mg/day Zinc 30–40 mg/day Melatonin 6 mg before bedtime (causes drowsiness) EARLY OUTPATIENT PROTOCOL 3 lvermectin1 0.2–0.4 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered* Use upper dose range if: 1) in regions with more aggressive variants; 2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors. Fluvoxamine 50 mg twice daily for 10–14 days. Add to ivermectin if: 1) minimal response after 2 days of ivermectin; 2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous comorbidities/risk factors. Avoid if patient is already on an SSRI. Nasopharyngeal Steamed essential oil inhalation 3 times a day (i.e. vapo-rub) Sanitation and/or chlorhexidine/benzydamine mouthwash gargles and Betadine nasal spray 2–3 times a day Vitamin D3 4,000 IU/day Vitamin C 500–1,000 mg twice a day Quercetin 250 mg twice a day Zinc 100 mg/day Melatonin 10 mg before bedtime (causes drowsiness) Aspirin 325 mg/day (unless contraindicated) Pulse Oximeter Monitoring of oxygen saturation is recommended (for instructions please see page 2 of this file) For optional medicines and an overview of the developments in prevention and treatment of COVID-19, please visit www.flccc.net/optional-medicines. * The dosing may be updated as further scientific studies emerge. 1 The safety of ivermectin in pregnancy has not been established. A discussion of benefits vs. risks with your provider is required prior to use, particularly in the 1st trimester. 2 To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask 3 For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treatment Protocol for COVID-19 on www.flccc.net Please regard our disclaimer and further information on page 2 of this document. flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 10 · Apr 26, 2021 Behavioral Prevention WEAR MASKS Must wear cloth, surgical, or N95 mask (without valve) in all indoor spaces with non- household persons. Must wear a N95 mask (with- out valve) during prolonged exposure to non-household persons in any conﬁned, poorly ventilated area. KEEP DISTANCE Until the end of the Covid-19 crisis, we recommend keep- ing a minimum distance of approx. 2 m / 6 feet in public from people who are not from your own household. WASH HANDS We recommend, after a stay during and after outings from home (shopping, sub- way etc.), a thorough hand cleaning (20–30 sec. with soap), or also to use a hand disinfectant in between. FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PREVENTION & TREATMENT PROTOCOLS FOR COVID-19 PREVENTION & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19 IVERMECTIN Summary of the Clinical Trials Evidence for Ivermectin in COVID-19 Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti- inflammatory properties in laboratory studies. In the past 4 months, numerous, con- trolled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin. Our comprehensive scientific review of these referenced trials on ivermectin can be found on www.flccc.net/flccc-ivermectin-in-the- prophylaxis-and-treatment-of-covid-19/ For a quick overview, a One-page Summary of our review on ivermectin can be found on www.flccc.net/one-page-summary-of-the-clini- cal-trials-evidence-for-ivermectin-in-covid-19/ Body weight conversion (kg/lb) for ivermectin dose in prevention and treatment of COVID-19 Body weight Conversion (1 kg ≈ 2.2 lbs) (doses calculated per upper end of weight range) Dose 0.2 mg/kg ≈ 0.09 mg/lb (Each tablet = 3 mg; doses rounded to nearest half tablet above) 70–90 lb 32–40 kg 8 mg (3 tablets = 9 mg) 91–110 lb 41–50 kg 10 mg (3.5 tablets) 111–130 lb 51–59 kg 12 mg (4 tablets) 131–150 lb 60–68 kg 13.5 mg (4.5 tablets) 151–170 lb 69–77 kg 15 mg (5 tablets) 171–190 lb 78–86 kg 16 mg (5.5 tablets) 191–210 lb 87–95 kg 18 mg (6 tablets) 211–230 lb 96–104 kg 20 mg (7 tablets = 21 mg) 231–250 lb 105–113 kg 22 mg (7.5 tablets=22.5 mg) 251–270 lb 114–122 kg 24 mg (8 tablets) 271–290 lb 123–131 kg 26 mg (9 tablets = 27 mg) 291–310 lb 132–140 kg 28 mg (9.5 tablets=28.5 mg) A summary of the published data supporting the rationale for Ivermectin use in our I-MASK+ protocol can be downloaded from www.flccc.net/flccc-ivermectin-summary For updates, references, and information on the FLCCC Alliance, the I-Mask+ Prevention & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit our website www.flccc.net flccc.net © 2020–2021 FLCCC Alliance · I-MASK+ Protocol · Version 10 · Apr 26, 2021 1 Quote Link to comment
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.